{"id":45025,"date":"2024-07-04T15:16:55","date_gmt":"2024-07-04T13:16:55","guid":{"rendered":"https:\/\/www.maiwald.eu\/publikationen\/is-the-medical-use-disclosure-standard-different-for-novelty-and-sufficiency-managing-ip-2024\/"},"modified":"2024-07-04T15:16:55","modified_gmt":"2024-07-04T13:16:55","slug":"is-the-medical-use-disclosure-standard-different-for-novelty-and-sufficiency-managing-ip-2024","status":"publish","type":"publikationen","link":"https:\/\/www.maiwald.eu\/ko\/publications\/is-the-medical-use-disclosure-standard-different-for-novelty-and-sufficiency-managing-ip-2024\/","title":{"rendered":"Is the medical use disclosure standard different for novelty and sufficiency?, Managing IP, 2024"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.maiwald.eu\/ko\/team\/eva-ehlich\/\">Eva Ehlich<\/a> and <a href=\"https:\/\/www.maiwald.eu\/ko\/team\/anja-fux\/\">Anja Fux<\/a> of Maiwald discuss an EPO board ruling relating to the standard of disclosure concerning the novelty and sufficiency of a therapeutic effect in the context of existing case law.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-45025","publikationen","type-publikationen","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/ko\/wp-json\/wp\/v2\/publikationen\/45025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/ko\/wp-json\/wp\/v2\/publikationen"}],"about":[{"href":"https:\/\/www.maiwald.eu\/ko\/wp-json\/wp\/v2\/types\/publikationen"}],"version-history":[{"count":0,"href":"https:\/\/www.maiwald.eu\/ko\/wp-json\/wp\/v2\/publikationen\/45025\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/ko\/wp-json\/wp\/v2\/media?parent=45025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}